NCT02585947Unknown4 期
A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 入组人数
- 90
- 试验地点
- 1
- 主要终点
- HBV reactivation: defined as an increase in HBV DNA at least 10 folds from nadir or reappearance of HBsA or HBeAg in blood during treatment.
研究概览
简要总结
The objective of this study is to analyze factors affecting Hepatitis B Virus (HBV) reactivation in anti-HBc positive patients with Non-Hodgkin's lymphoma treated with rituximab and compare HBV reactivation rates by duration of prophylactic treatment with tenofovir to contribute to the establishment of an effective prevention strategy.
详细描述
This study will be conducted in a randomized, open-label, multi-center design. On Day 1 of chemotherapy, approximately 90 subjects screened and determined eligible will be randomized to either Group A or Group B in a 1:1 manner for study participation.
- Group A: Upon the EOC, subjects will receive tenofovir 300mg for approximately 6 months (24 weeks) and undergo treatment and follow-up every 12 weeks for up to 72 weeks post chemotherapy.
- Group A: Upon the EOC, subjects will receive tenofovir 300mg for approximately 12 months (48 weeks) and undergo treatment and follow-up every 12 weeks for up to 72 weeks post chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 81 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age of ≥ 18 (Women must not be pregnant or breast-feeding; all females of childbearing potential must have a blood test or urine study during screening to rule out pregnancy. / A woman of childbearing potential must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 26 weeks after the last dose of tenofovir. / If the Investigator obtains information concerning the pregnancy of a female patient, the Investigator must terminate the study drug immediately in that patient, and report the information to IRB in the same manner as for SAE reporting)
- •CD 20 positive patients with Non-Hodgkin's lymphoma who are planned to receive anticancer treatment with rituximab based chemotherapy and A. ECOG performance status 0-2 B. Adequate renal function: serum creatinine level < 2 mg/dL (177 μmol/L) C. Adequate hematological function: hemoglobin ≥ 9g/dL, absolute neutrophil count (ANC) ≥ 1,500/μL, platelet count ≥ 75,000/μL, unless abnormalities are due to bone marrow involvement by lymphoma D. Expected residual life ≥ 6 months
- •Serum HBsAg negative, anti-HCV negative, but anti-HBc positive
- •ALT < 80IU/mL, serum bilirubin < 3.0mg/dL, unless abnormalities are due to liver involvement by lymphoma or tumor lysis syndrome
- •Individuals who were given and understood detailed explanations about this study, voluntarily decided to participate in the study, and provided written informed consent
排除标准
- •Child-Pugh class C
- •Other chronic liver diseases such as autoimmune hepatitis or Wilson's disease
- •Patient who has hypersensitivity to study drug
- •Patient who has galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption
- •Patient who is pregnant or on lactating. Or who has plans for pregnant or lactation during study period even the partner of the male patient
研究组 & 干预措施
tenofovir for 24 weeks
Experimental
- prophylactic (preemptive) treatment
- 300mg for 24 weeks
- once daily
干预措施: Tenofovir (Drug)
tenofovir for 48 weeks
Experimental
- prophylactic (preemptive) treatment
- 300mg for 48 weeks
- once daily
干预措施: Tenofovir (Drug)
结局指标
主要结局
HBV reactivation: defined as an increase in HBV DNA at least 10 folds from nadir or reappearance of HBsA or HBeAg in blood during treatment.
时间窗: after 48 week from the End of treatment
次要结局
- Hepatitis flare: defined as elevation of HBV viral load more than 2,000IU/ml from the baseline or by the reappearance of HBsAg and elevation of ALT at least 100IU/ml from the baseline.(after 48 week from the End of treatment)
研究者
Yoon Jun Kim
Professor
Seoul National University Hospital
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Hepatitis B Virus Reactivation After Withdrawal of Prophylactic Antiviral Therapy in Lymphoma PatientsHematologic DiseasesLymphomaHepatitis BHepatitisNCT02108444Peking University107
Unknown
2 期
Incidence of Hepatitis B Virus (HBV) Reactivation in HBsAg Negative/HBcAb Positive Lymphoma Patients Treated With RCHOPLymphomaNCT01210287Fudan University110
已完成
不适用
Risk of Hepatitis B Virus Reactivation in Patients Undergoing AllograftingHepatitis B VirusAllograftHematological MalignanciesNCT00876148Azienda Ospedaliera San Giovanni Battista
Unknown
不适用
Pegylated Interferon Alpha-2b Monotherapy Versus Combination With Entecavir in HBeAg-negative Chronic Hepatitis BChronic Hepatitis BNCT01243281Chulalongkorn University126
已完成
1 期
A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus InfectionHepatitis B, ChronicNCT05123599Janssen Research & Development, LLC24